share_log

Braxia Scientific Reports Q2 2024 Financial Results and Provides Corporate Update

Braxia Scientific Reports Q2 2024 Financial Results and Provides Corporate Update

Braxia Scientific報告了2024年第二季度財務業績並提供了公司最新情況
newsfile ·  2023/11/30 20:50

Toronto, Ontario--(Newsfile Corp. - November 30, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia Scientific", or the "Company"), a medical research company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its financial statements and management discussion and analysis for the three months and six months ended September 30, 2023. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval (SEDAR+), the electronic filing system for the disclosure documents of issuers across Canada, at .

安大略省多倫多--(Newsfile Corp.,2023年11月30日)-Braxia Scientific Corp.(CSE:BRAX)(OTC Pink:BRAXF)(FSE:4960)(“Braxia Scientific”,或 “公司”),一家擁有爲抑鬱症和相關疾病提供創新****和迷幻藥療法的診所的醫學研究公司,今天宣佈提交這三家公司的財務報表以及管理層討論和分析截至 2023 年 9 月 30 日的六個月零六個月。完整的財務報表以及相關的管理層討論和分析可以在電子文件分析和檢索系統(SEDAR+)中找到,該系統是加拿大各地發行人披露文件的電子歸檔系統,網址爲。

Dr. Roger McIntyre, CEO, Braxia Scientific commented, "Our clinics experienced higher treatment volumes in the first half of fiscal 2024 resulting in strong revenue growth. This demonstrates the demand for critical mental health treatments and therapies that our team of specialized psychiatrists, doctors and nurses provide across our clinical footprint. Our team has continued to focus on reducing expenses and improving efficiencies while also looking to add novel therapies and other support services to our clinical platform to further improve revenues."

Braxia Scientific首席執行官羅傑·麥金太爾博士評論說:“我們的診所在2024財年上半年的治療量有所增加,從而實現了強勁的收入增長。這表明了我們的專業精神科醫生、醫生和護士團隊在我們的臨床足跡中提供的關鍵心理健康治療和療法的需求。我們的團隊繼續專注於減少開支和提高效率,同時還希望爲我們的臨床平台增加新療法和其他支持服務,以進一步提高收入。”

"Looking ahead, the Board has formally initiated a process to explore strategic alternatives and alternative sources of capital or partnerships that may be available to the Company following continued challenges in the economic environment and in accessing capital through public markets. While I remain confident in the continued growth of our clinics, if we are unable to raise additional funding in the short term, we will look at alternate courses of actions including, but not limited to, further cost reductions, restructuring and the potential scaling back of clinic locations."

“展望未來,董事會已正式啓動一項進程,探討在經濟環境和通過公開市場獲得資本方面持續面臨挑戰的情況下,公司可能獲得的戰略替代方案和替代資本或合作伙伴關係。儘管我對診所的持續增長仍然充滿信心,但如果我們無法在短期內籌集更多資金,我們將考慮其他行動方案,包括但不限於進一步削減成本、重組和可能縮減診所地點。”

Q2 2024 Financial Summary and Recent Highlights

2024 年第二季度財務摘要和近期亮點

  • Revenue increased 30.5% to $0.594 million year-over-year for the three months ended September 30, 2023.
  • Revenue increased 36.8% to $1.19 million year-over-year for the six months ended September 30, 2023.
  • Net loss was $0.275 million for the three months ended September 30, 2023, compared to a net loss of $2.16 million for the three months ended September 30, 2022.
  • Net loss was $1.08 million for the six months ended September 30, 2023, compared to a net loss of $3.13 million for the six months ended September 30, 2022.
  • As at September 30, 2023, the Company's cash and cash equivalents were $0.701 million with a working capital deficit of $0.961 million.
  • 截至2023年9月30日的三個月,收入同比增長30.5%至59.4萬美元。
  • 截至2023年9月30日的六個月中,收入同比增長36.8%,達到119萬美元。
  • 截至2023年9月30日的三個月,淨虧損爲27.5萬美元,而截至2022年9月30日的三個月淨虧損爲216萬美元。
  • 截至2023年9月30日的六個月中,淨虧損爲108萬美元,而截至2022年9月30日的六個月淨虧損爲313萬美元。
  • 截至2023年9月30日,該公司的現金及現金等價物爲70.1萬美元,營運資金赤字爲96.1萬美元。

Corporate Update

公司最新消息

  • The Company continued to make progress on its revenue generation and expense reduction initiatives as well as streamlining its operations to prioritize preservation of capital. After further review and in consultation with its legal advisors, the Board of Directors has decided to formally initiate a process to explore strategic alternatives that may be available to the Company to unlock shareholder value. The comprehensive process will begin immediately and will evaluate a broad range of options, including a potential sale of the Company, a merger or other business combination, a sale of all or a portion of the Company's assets, strategic investment or other significant transaction. Braxia has received strategic inquiries from multiple parties over the past few months.
  • 該公司繼續在創收和削減支出方面取得進展,並精簡運營以優先保護資本。經過進一步審查並與法律顧問協商,董事會決定正式啓動一項程序,探討公司可能爲釋放股東價值而可能採用的戰略替代方案。全面的流程將立即開始,並將評估廣泛的選擇,包括可能出售公司、合併或其他業務合併、出售公司全部或部分資產、戰略投資或其他重大交易。在過去的幾個月中,Braxia收到了來自多方的戰略詢問。
  • The Company has not set a timetable for completion of the process and does not intend to provide any updates on developments unless and until the Company executes a definitive agreement with respect thereto, or the Board otherwise determines that an update is appropriate or required.
  • While the Company intends to evaluate all options fairly to maximize shareholder value, there can be no assurance that the strategic review process will result in any transaction, or if a transaction is undertaken, as to its terms or timing.
  • The Company also announced the resignation of Olga Cwiek from Braxia Scientific's Board of Directors effective November 28, 2023. Peter Rizakos, Chief Legal Officer, has been appointed to the Board of Directors. Additionally, the Company announced the departure of Stephen Brooks, Chief Financial Officer, to pursue an opportunity in the private sector. Peter Rizakos, Chief Legal Officer, has been named Chief Financial Officer.
  • 公司尚未制定完成該流程的時間表,也不打算提供任何最新進展,除非公司就此達成最終協議,或者董事會以其他方式確定更新是適當或需要的。
  • 儘管公司打算公平評估所有選擇以最大限度地提高股東價值,但無法保證戰略審查過程會導致任何交易,也無法保證如果進行交易,則無法保證其條款或時機會得出任何協議。
  • 該公司還宣佈,奧爾加·茨維克辭去Braxia Scientific董事會的職務,自2023年11月28日起生效。首席法務官彼得·裏扎科斯被任命爲董事會成員。此外,該公司宣佈首席財務官斯蒂芬·布魯克斯離職,前往私營部門尋求機會。首席法務官彼得·裏扎科斯被任命爲首席財務官。

"We thank both Olga and Stephen for their service to Braxia Scientific and wish them success in their future endeavors," said Dr. McIntyre.

麥金太爾博士說:“我們感謝奧爾加和斯蒂芬爲Braxia Scientific提供的服務,並祝願他們在未來的工作中取得成功。”

About Braxia Scientific Corp.

關於布拉夏科學公司

Braxia Scientific is a medical research and telemedicine company with clinics that provide innovative ketamine treatments for persons with depression and related disorders. Through its medical solutions, Braxia aims to reduce the illness burden of brain-based disorders, such as major depressive disorder among others. Braxia is primarily focused on (i) owning and operating multidisciplinary clinics, providing treatments in-person and virtually for mental health disorders, and (ii) research activities related to discovering and commercializing novel drugs and delivery methods. Braxia seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform. Through its wholly owned subsidiary, Braxia Health (formerly the Canadian Rapid Treatment Center of Excellence Inc.), operates multidisciplinary community-based clinics offering rapid-acting treatments for depression located in Mississauga, Toronto, Kitchener-Waterloo, Ottawa, and Montreal.

Braxia Scientific是一家醫學研究和遠程醫療公司,其診所爲抑鬱症和相關疾病患者提供創新的****治療方法。通過其醫療解決方案,Braxia旨在減輕重度抑鬱症等腦基疾病的疾病負擔。Braxia主要專注於(i)擁有和運營多學科診所,爲心理健康障礙提供面對面和虛擬治療,以及(ii)與發現和商業化新藥物和給藥方法相關的研究活動。Braxia尋求通過其知識產權開發平台開發****及其衍生物和其他迷幻產品。通過其全資子公司Braxia Health(前身爲加拿大卓越快速治療中心有限公司),在密西沙加、多倫多、基奇納-滑鐵盧、渥太華和蒙特利爾經營提供抑鬱症速效治療的多學科社區診所。

ON BEHALF OF THE BOARD

代表董事會

"Dr. Roger S. McIntyre"
Dr. Roger S. McIntyre

“羅傑·S·麥金太爾博士”
羅傑·麥金太爾博士

Chairman & CEO

董事長兼首席執行官

- 30 -

-30-

FOR FURTHER INFORMATION PLEASE CONTACT:

欲了解更多信息,請聯繫:

Braxia Scientific Corp.
Tel
: 416-762-2138
Email: info@braxiascientific.com
Website:

布拉夏科學公司
電話
: 416-762-2138
電子郵件: info@braxiascientific.com
網站:

The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

CSE 尚未審查本新聞稿的準確性或充分性,也不承擔任何責任。

Forward-Looking Information Cautionary Statement

前瞻性信息警示聲明

This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance are "forward-looking statements."

本新聞稿包含適用證券法所指的前瞻性陳述。所有不是歷史事實、未來估計、計劃、計劃、預測、預測、目標、假設、預期或未來表現信念的陳述都是 “前瞻性陳述”。

Forward-Looking statements include statements about the intended promise of ketamine-based treatments for depression, the potential for ketamine or other psychedelics to treat other mental health conditions, the ability of Braxia's business strategies, including in telemedicine, to address the unmet need for mental health disorders or expand or accelerate the growth of Braxia. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events, or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risks and uncertainties include, among others, the failure of ketamine, psilocybin and other psychedelics to provide the expected health benefits and unanticipated side effects, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licenses and engaging in activities that could be later determined to be illegal under domestic or international laws. Ketamine and psilocybin are currently Schedule I and Schedule III controlled substances, respectively, under the Controlled Drugs and Substances Act, S.C. 1996, c. 19 (the "CDSA") and it is a criminal offence to possess such substances under the CDSA without a prescription or a legal exemption. Health Canada has not approved psilocybin as a drug for any indication, however ketamine is a legally permissible medication for the treatment of certain psychological conditions. It is illegal to possess such substances in Canada without a prescription.

前瞻性陳述包括有關****類抑鬱症治療的預期前景、****或其他迷幻藥治療其他心理健康疾病的可能性、Braxia的商業戰略(包括遠程醫療)解決未得到滿足的心理健康障礙需求或擴大或加速Braxia增長的能力。此類前瞻性陳述涉及已知和未知的風險、不確定性和其他因素,這些因素可能導致實際結果、事件或發展與此類前瞻性陳述所表達或暗示的任何未來業績、事件或發展存在重大差異。除其他外,此類風險和不確定性包括****、迷幻藥和其他迷幻藥未能提供預期的健康益處和意想不到的副作用,依賴於獲得和維持監管部門的批准,包括獲得和續訂聯邦、省、市、地方或其他許可證,以及從事根據國內或國際法律日後可能被認定爲非法的活動。根據《管制藥物和物質法》(S.C. 1996,c. 19),****和迷幻藥目前分別是附表一和附表三的管制物質,在沒有處方或法律豁免的情況下根據CDSA擁有此類物質是刑事犯罪。加拿大衛生部尚未批准psilocybin作爲任何適應症的藥物,但是****是法律允許的用於治療某些心理疾病的藥物。在加拿大沒有處方的情況下擁有此類藥物是非法的。

These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements.

應仔細考慮這些因素,並提醒讀者不要過分依賴此類前瞻性陳述。

Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, including the Amended and Restated Listing Statement dated April 15, 2021 and its most recent MD&A, which are available at . There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements.

儘管公司試圖確定可能導致實際行動、事件或結果與前瞻性陳述中描述的存在重大差異的重要風險因素,但可能還有其他風險因素導致行動、事件或結果與預期、估計或預期的有所不同。識別可能影響財務業績的風險和不確定性的其他信息包含在公司向加拿大證券監管機構提交的文件中,包括2021年4月15日的經修訂和重述的上市聲明及其最新的MD&A,可在以下網址查閱。無法保證前瞻性陳述會被證明是準確的,因爲實際結果和未來事件可能與前瞻性陳述中的預期存在重大差異。

To view the source version of this press release, please visit

要查看本新聞稿的源版本,請訪問

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論